Key Drug Makers in Review - Pfizer (NYSE:PFE), Merck & Co (NYSE:MRK), Keryx Biopharmaceuticals (NASDAQ:KERX) - ABT, BMY, JNJ

Half Moon Bay, CA -- (SBWIRE) -- 02/06/2013 -- OrbitStocks.com is committed to discovering hot penny stock alerts with the potential to make large percent gains. Orbit Stocks have been in the penny stock market for several years and know how the game works. Their investing knowledge is a culmination of constant market analysis and trading experience. Orbit Stocks have a proven track record, and they provide their members with free, timely alerts.

Pfizer Inc.(NYSE:PFE) stock is at $27.51, up1.25 percent from its previous close of $27.17. The stock opened the session at $27.24 and touched its highest price point at $27.60. Pfizer stock’s lowest price point for the session stood at $27.23. The company is seeking an approval from the Competition Tribunal for the planned takeover of its baby nutrition division by Nestle, a deal which could raise the prices of the products.

Stocks graphical chart shows a bullish trend during its last one month’s trading session. It remained positive with 11.92% during previous three months trade.

Its today’s volume is 27.40 million shares in comparison to its usual trading volume of 34.97 million shares. Its beta value stands at 0.72 points. Currently stocks EPS is $1.26 while its price to earning ratio is 21.84.

Will PFE Continue To Move Higher? Find Out Here

Merck & Co., Inc.(NYSE:MRK)stock is at $41.43, up 1.42 percent from its previous close of $40.85. Its today’s volume is 21.31 million shares in comparison to its usual trading volume of 15.67 million shares. The company has recently been ordered to pay $285,000 in a lawsuit over the risks of its osteoporosis drug Fosamax.

The stock opened the session at $41.05 and touched its highest price point at $41.48. Merck’s lowest price point for the session stood at $40.93, and its 52 week price range stood at $36.91 - $48.00. The company has total of 3.04billion outstanding shares and its total market capitalization is $125.95billion. Its beta value stands at 0.32 times and earning per share was $2.17.

Previous 5 days graph demonstrated a negative move of -4.67%. MRK’s quarterly performance remained red with the percentage of -9.28, while its year to date performance showed that the stock advanced overall +1.20%.

Why Should Investors Buy MRK After The Recent Gain? Just Go Here and Find Out

Keryx Biopharmaceuticals(NASDAQ:KERX) opened the session at $6.66 and remained in $6.62 and $7.30 price range during the session. The stock is 8.54 percent higherat $7.12. Volume closed the day at 16.98 million shares, its average volume being 10.60 million shares.

The company has total of 71.93 million outstanding shares and its total market capitalization is $512.11 million. Its beta value stands at 3.83 times and earning per share was -$0.38.

KERXwas a gainer in the 5 days activity and jumped about +107.58%. The one month performance of stock was positive and it scored more than +160.81%.

What was the Moving Force behind KERXOn Bullish Run? Read This Research Report

Abbott Laboratories(NYSE:ABT) traded in the range of $33.65 and $33.99 in its previous trading session after Jefferies Group reiterated its “buy” rating on the stock. It recorded the volume of 14.14 million shares, in comparison its average daily trading volume of 13.57 million shares. The company has total of 3.16billion outstanding shares and its total market capitalization is $106.98billion.

Company’s year to date performance remained quiet optimistic with the rise of 3.33%. If we look at last 6 months of trade that is in bullish zone with an increase of 1.62%

The stock opened at $33.68 and its closing price for the day was $33.84, up1.01 percent from its previous close of $33.50. The beta of the ABTstands at 0.20. 52 week range of the stock is $31.64 -$72.47.

For How Long ABT will Fight for Profitability? Read This Trend Analysis report

Bristol Myers Squibb Co.(NYSE:BMY) experienced a plunge of -0.03% to a market valuation of $36.51 per share for previous trading session. After opening the day at $36.67 per share, volume surged to 10.77M, moving forward from its daily average volume of 9.78 million shares. Beta value for the Company stands at 0.44, indicating its risk level. The stock remained in $36.50 and $37.09 price range during the session

Company’s graphical value indicates these stories about the stocks:

During last 5 trades the stock plummeted almost -0.49%. During last one month it rose with the percentage of 9.48. Its year to date performance remained progressive with 12.03%.

Stock touched its 52 week highest price point at $37.09. Bristol Myers Squibb stock’slowest price point for52 weeks stood at $30.64.

Will BMY Get Buyers Even After The Recent Rally? Find Out Here

Johnson & Johnson(NYSE:JNJ) opened the session at $74.49 and remained in $74.47 and $74.82 price range during the session. The stock is 0.74 percent higherat $74.66. Volume closed the day at 10.23 million shares, its average volume being 10.30 million shares.

The company has total of 2.77billion outstanding shares and its total market capitalization is $206.90 million. Its beta value stands at 0.54 times and earning per share was $5.10.

JNJwas a gainer in the 5 days activity and jumped about +1.00%. The one month performance of stock was positive and it scored more than +4.35%.

For How Long JNJ’s Gloss will Attract Investors? Find out via this report

About OrbitStocks.com
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.

Disclaimer
Orbit Stocks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.